Biosysen Limited (01355) filed its Monthly Return for Equity Issuer for the period ended 31 July 2026, confirming that its share capital structure remained unchanged during the month.

The company’s authorised share capital was steady at 2.00 billion ordinary shares with a par value of HKD 0.01 each, equivalent to HKD 20.00 million. Issued share capital also held constant at 1.19 billion ordinary shares, with no treasury shares reported.

No new share options, warrants, convertibles, or other equity-linked instruments were issued, and there were no repurchases, redemptions, or other movements in the share base.

Biosysen affirmed compliance with the Main Board’s minimum public float threshold of 25%, indicating an adequate proportion of freely tradable shares in the market.

The submission was signed by Company Secretary Lee Pak Chung, who confirmed adherence to all applicable listing rules and regulatory requirements.